References
1. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10:720–741.
2. Songer TJ, Zimmet PZ. Epidemiology of type II diabetes: an international perspective. Pharmacoeconomics 1995;8:1–11.
3. Güvener N, Akcan Y, Paksoy I, et al. Helicobacter pylori associated gastric pathology in patients with type II diabetes mellitus and its relationship with gastric emptying: the Ankara study. Exp Clin Endocrinol Diabetes 1999;107:172–176.
4. Gentile S, Turco S, Oliviero B, et al. The role of autonomic neuropathy as a risk factor of Helicobacter pylori infection in dyspeptic patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 1998;42:41–48.
5. Demir M, Gokturk HS, Ozturk NA, et al. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci 2008;53:2646–2649.
6. Candelli M, Rigante D, Marietti G, et al. Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients. Pediatrics 2003;111:800–803.
7. Sargýn M, Uygur-Bayramicli O, Sargýn H, et al. Type 2 diabetes mellitus affects eradication rate ofHelicobacter pylori. World J Gastroenterol 2003;9:1126–1128.
8. Demir M, Gokturk HS, Ozturk NA, et al. Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study. Am J Med Sci 2009;338:459–464.
9. Tong JL, Ran ZH, Shen J, et al. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009;34:41–53.
10. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772–781.
11. Gasbarrini A, Ojetti V, Pitocco D, et al. Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999;11:713–716.
12. Gasbarrini A, Ojetti V, Pitocco D, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol 2000;35:260–263.
13. Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet 2007;370:1010–1012.
14. Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353–1357.
15. Uygun A, Kadayifci A, Yesilova Z, et al. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. Clin Ther 2008;30:528–534.
16. De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006;144:94–100.
17. Marhoffer W, Stein M, Maeser E, et al. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992;15:256–260.
18. Bessman AN, Sapico FL. Infections in the diabetic patient: the role of immune dysfunction and pathogen virulence factors. J Diabetic Complications 1992;6:258–262.
19. Mégraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997;11(suppl 1):43–53.
20. Demir M, Gokturk HS, Ozturk NA, et al. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South Med J 2009;102:1116–1120.
21. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991;20:477–490.
22. Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus. Am J Gastroenterol 1987;82:29–35.
23. Horowitz M, Wishart JM, Jones KL, et al. Gastric emptying in diabetes: an overview [Review]. Diabet Med 1996;13:S16–S22.
24.Groop LC, Luzi L, DeFronzo RA, et al. Hyperglycaemia and absorption of sulphonylurea drugs. Lancet 1989;2:129–130.
25. Tooke JE. Microvascular haemodynamics in diabetes mellitus [Review]. Clin Sci (Lond)1986;70:119–125.
26. Zatz R, Brenner BM. Pathogenesis of diabetic microangiopathy. The hemodynamic view. Am J Med 1986;80:443–453.
27. Kong MF, Macdonald IA, Tattersall RB. Gastric emptying in diabetes. Diabet Med 1996;13:112–119.
28. Perri F, Villani MR, Festa V, et al. Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy.’ Aliment Pharmacol Ther 2001;15:1023–1029.
29. Huang JQ, Hunt RH. Treatment after failure: the problem of “nonresponders” [Review]. Gut1999;45(suppl 1):140–144.
30. Huang JQ, Zheng GF, Hunt RH, et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol 2005;11:2726–2732.
31. Sezgin O, Aslan G, Altintaş E, et al. Detection of point mutations on 23S rRNA of Helicobacter pyloriand resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin, Turkey. Turk J Gastroenterol 2008;19:163–167.